



In vitro study on α -amylase inhibitory and α -glucosidase of a new stigmastane-type steroid saponin from the leaves of *Vernonia amygdalina*

Hoang Le Tuan Anh, Le Ba Vinh, Le Thi Lien, Pham Viet Cuong, Masayoshi Arai, Tran Phuong Ha, Hoang Ngoc Lin, Ton That Huu Dat, Le Canh Viet Cuong & Young Ho Kim

To cite this article: Hoang Le Tuan Anh, Le Ba Vinh, Le Thi Lien, Pham Viet Cuong, Masayoshi Arai, Tran Phuong Ha, Hoang Ngoc Lin, Ton That Huu Dat, Le Canh Viet Cuong & Young Ho Kim (2019): *In vitro* study on α -amylase inhibitory and α -glucosidase of a new stigmastane-type steroid saponin from the leaves of *Vernonia amygdalina*, Natural Product Research, DOI: [10.1080/14786419.2019.1607853](https://doi.org/10.1080/14786419.2019.1607853)

To link to this article: <https://doi.org/10.1080/14786419.2019.1607853>




View supplementary material 



Published online: 17 Jun 2019.



Submit your article to this journal 



View Crossmark data 



In vitro study on α -amylase inhibitory and α -glucosidase of a new stigmastane-type steroid saponin from the leaves of *Vernonia amygdalina*

Hoang Le Tuan Anh^{a,b,*}, Le Ba Vinh^{d,e*}, Le Thi Lien^{a,b}, Pham Viet Cuong^a, Masayoshi Arai^c, Tran Phuong Ha^a, Hoang Ngoc Lin^a, Ton That Huu Dat^a, Le Canh Viet Cuong^a and Young Ho Kim^d

^aMien Trung Institute for Scientific Research Vietnam Academy of Science and Technology, Hue city, Vietnam; ^bGraduate University of Science and Technology Vietnam Academy of Science and Technology (VAST), Hanoi, Vietnam; ^cResearch Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan; ^dCollege of Pharmacy, Chungnam National University, Daejeon, Republic of Korea; ^eInstitute of Marine Biochemistry Vietnam Academy of Science and Technology, Ha Noi, Vietnam

ABSTRACT


Using various chromatographic separations, four compounds, including one new steroid saponin named vernoamyoside E (**1**), were isolated from the leaves of the Vietnamese medicinal plant *Vernonia amygdalina* Delile (Asteraceae). Their structures were established by spectroscopic methods such as 1D- and 2D-NMR, HR-ESI-MS, and HPLC analysis. The inhibitory activities against α -glucosidase and α -amylase of the isolated compounds from *V. amygdalina* were reported for the first time. The results indicated that compound **1** significantly inhibited both against α -amylase and α -glucosidase activity.

ARTICLE HISTORY

Received 27 December 2018
Accepted 31 March 2019


KEYWORDS

Vernonia amygdalina;
Asteraceae; vernoamyoside E;
 α -amylase inhibitory;
 α -glucosidase inhibitory



CONTACT Young Ho Kim ✉ yhk@cnu.ac.kr College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea; Pham Viet Cuong ✉ cuongwg@yahoo.com Mien Trung Institute for Scientific Research Vietnam Academy of Science and Technology, 321 Huynh Thuc Khang, Hue city, Thua Thien Hue, Vietnam

*These authors are contributed equally to this work.

 Supplemental data for this article can be accessed at <https://doi.org/10.1080/14786419.2019.1607853>.

© 2019 Informa UK Limited, trading as Taylor & Francis Group

1. Introduction

Vernonia amygdalina Del. is a shrub or small tree that is mainly grown in tropical areas of Africa (Atangwho et al. 2012). In Africa, it can be used as a traditional treatment for diabetes, nausea, dermatitis, arthritis, ascariasis, stomachache, anaemia, jaundice, pneumonia, fever, tonsillitis, schistosomiasis, malaria, amoeba, and intestinal upsets (Farombi and Owioye 2011). The principal chemical components have shown that *V. amygdalina* contains steroids, polyphenolics, alkaloids, anthraquinones, lignans, flavonoids, and coumarins (Liu et al. 2019). Biological activities of extracts and isolated compounds from *V. amygdalina* have been reported, such as antibacterial, antifungal, antiparasite, antiviral, anticancer, anti-obesity, antioxidant, antihypertensive, and liver protective activity (Atangwho et al. 2012; Atangwho et al. 2013; Igile et al. 1994; Kupchan et al. 1969; Taiwo et al. 2009; Yeap et al. 2010). In continuation to study secondary metabolites and evaluation anti-diabetic compounds of Vietnamese medicinal plants, herein, we reported the isolation and structural elucidation of four steroid saponins including one new compound (**1**) from the leaves of *V. amygdalina*.

2. Results and discussion

In the present study, the methanol (MeOH) extract from the leaves of *V. amygdalina* were evaluated to against α -amylase and α -glucosidase activity. In this regard, the MeOH extract significantly inhibited both against α -amylase and α -glucosidase activity with IC_{50} 0.64 ± 0.12 mg/mL and 1.78 ± 0.31 mg/mL, respectively. Anti-diabetic guide fraction and purification led to isolation of four compounds including one new compound (**1**), and three known compounds (**2–4**) (Figure 1). The known compounds were identified vernoniacum B (**2**) (Ma et al. 2016), vernonioside B₁ (**3**) (Jisaka et al. 1992), and vernonioside B₂ (**4**) (Jisaka et al. 1993) by comparing their spectroscopic data ($[\alpha]_D^{20}$, 1D, 2D NMR, MS) with reported values.

Vernoamyoside E (**1**), $[\alpha]_D^{20} +24.7$ (c 0.15, MeOH), was obtained as a white amorphous powder. The molecular formula (C₃₆H₅₆O₁₁) of **1** was determined by HR-ESI-MS with a sodium molecular ion peak at m/z 687.3708 $[M+Na]^+$ (calcd for C₃₆H₅₆NaO₁₁⁺, 687.3720). The NMR spectra (Supplementary material) are indicative of a steroid saponin with three *tert*-methyl proton signals at δ_H 0.57, 0.93, and 1.42 (each, 3H, s), two doublet methyl signals at δ_H 0.94 (3H, d, $J=7.0$ Hz, H-26), 0.95 (3H, d, $J=7.0$ Hz, H-27), a methoxy signal at δ_H 3.21 (3H, s, 28-OCH₃), and two doublet olefinic protons at δ_H 5.43 (1H, d, $J=5.0$ Hz, H-7), 5.53 (1H, d, $J=5.5$ Hz, H-11), as well as one anomeric proton signals at δ_H 4.42 (1H, d, $J=8.0$ Hz, H-1'). The ¹³C-NMR spectrum of **1** exhibited the signals of 36, of which 6 carbon signals were assigned to a sugar unit and the remaining 29 carbon signals were assigned to a steroid aglycon (one of the main constituents of *V. amygdalina*) on the basis 1D-2D-NMR. Analysis ¹³C-NMR signals were indicated an isopropyl unit at δ_C 32.7 (C-25), 17.4 (C-26), 18.1 (C-27), three hydroxylated carbons at δ_C 81.0 (C-22), 91.3 (C-23), 83.2 (C-24), two hemiacetal carbons at δ_C 100.0 (C-21), 112.9 (C-28), a methoxy group at δ_C 48.3 (28-OCH₃), and a methyl group at δ_C 17.4 (C-29) by combined HSQC signals. The aglycon of **1** was identified as $\Delta^{7,9(11)}$ dienstigmastane glycoside previously reported from *V. amygdalina* by clear agreement of its ¹H and ¹³C NMR data (Quasie et al. 2016). Comparison of the ¹H, and ¹³C-NMR data of **1** with those

of vernoniosides B₁ (**3**) demonstrated that two compounds were almost identical in the same NMR solvent. The only difference between these two compounds was the replacement of the hydroxyl group at C-16 (δ_C 28.0 ppm). In addition, the NOESY spectrum revealed significant cross-peaks between H-20 and each proton at C-21, C-22, and C-23. H-22 and each proton at C-21, and C-23, H-23 and one of methyl (H-27) of the isopropyl group, and H-22 and the methoxy group showing that all of the hydrogens at C-20-C-23, and the isopropyl and the methoxy groups are β -orientated. Furthermore, absolute configurations of the sugar moieties were identified as β -D-glucopyranosyl by coupling constants of anomeric position δ_H 4.42 ($J=8.0$, H-1'), and acid hydrolysis of **1** followed by TLC and HPLC analysis in comparison with the authentic samples ([Supplementary data](#)). Attachment of the monosaccharide chain at C-3 of the aglycon was confirmed by HMBC correlation of the anomeric proton H-3 (δ_H 3.71) with C-1' (δ_C 102.6). Therefore, the structure of **1** was established as (22*R*,23*S*,24*R*,28*S*)-3 β -glucosyl-28-methoxy-7,8,9,11-tetradehydro-21,24-dihydroxy-21,23:22,28-diepoxy-5 α -stigmastane.

Diabetes mellitus is a chronic disease that affects millions of people worldwide. To date, much effort has been studied to identify effective with α -amylase, and α -glucosidase inhibitors from natural sources by isolation compounds develop functional food for use against diabetes (Fatmawati et al. 2011). Previously, we were investigated that isolated compounds which were exhibited potential treatment of diabetes from *Rosa rugosa*, and *Ecklonia cava* (Park et al. 2018; Thao et al. 2014). Bitter leaf (*V. amygdalina*) is a popular vegetable commonly consumed and which has been employed in traditional medicine for the prevention and management of diabetes and hypertension (Saliu et al. 2012). In this study, the inhibitory effects of the MeOH extract, and isolated compounds against α -amylase and α -glucosidase were evaluated. As the obtained results, compound **1** exhibited potent inhibitory activity against α -glucosidase enzyme, more than positive control on both 100 and 500 μ g/mL concentrations with values 50.17 ± 1.03 μ g/mL and 60.03 ± 3.85 μ g/mL, respectively. While, compounds **1**, **2**, and **3** showed significant inhibition against α -amylase enzyme with IC₅₀ values of 102.23, 83.17, and 87.09 μ g/mL, respectively when compared with that of a positive control, acarbose, 6.3 μ g/mL.

All compounds (**1–3**) have shown significantly against both α -amylase and α -glucosidase. The most active compound **1**, not only indicated a more potent α -glucosidase inhibitory activity than acarbose (positive control) but also showed significant activity against α -amylase.

Given the potential against both α -amylase and α -glucosidase of *V. amygdalina* extracts, and isolated compounds, compound **1** might be potential candidate for further investigation on the molecular mechanisms of action on specific anti-diabetic targets.

3. Experimental

3.1. General experimental procedures

Optical rotations were determined on a JASCO P-2000 polarimeter (Hachioji, Tokyo, Japan). The high-resolution electrospray ionisation mass spectra (HR-ESI-MS) were obtained from a MicroQ-TOF III mass spectrometer (Bruker Daltonics, 255748

Germany). IR spectra were obtained on a Bruker TENSOR 37 FT-IR spectrometer. The NMR spectra were recorded on a Bruker Advance III HD 500 FT NMR spectrometers with TMS as an internal standard. HPLC was used with Kinetex C₁₈ column (250 × 20.0 mm, 5 μm; Phenomenex, Torrance, CA). Column chromatography (CC) was performed on silica gel (Kiesel gel 60, 70–230 mesh and 230–400 mesh, Merck, Darmstadt, Germany), YMC*GEL (ODS-A, 12 nm S-150 μm, YMC Co., Ltd.) and Sephadex LH-20 (Sigma-Aldrich, USA) resins. TLC used pre-coated silica gel 60 F₂₅₄ (1.05554.0001, Merck) and RP-18 F_{254S} plated (1.15685.0001, Merck), and compounds were visualized by spraying aqueous 10% H₂SO₄ and heating for 3–5 min.

3.2. Biological material

The leaves of *V. amygdalina* were collected at Phong Dien, Thua Thien Hue Province, Vietnam in August 2017, and were identified by Dr. Nguyen Quynh Nga (Institute of Medicinal Material, Vietnam). A voucher plant (MISR-2017-14) has been deposited at Mien Trung Institute for Scientific Research, VAST, Vietnam.

3.3. Assay for α-glucosidase inhibition

The α-glucosidase enzyme inhibition assay was carry out according to similar the previously method (Luyen et al. 2019) and provide in [supplementary data](#).

3.4. Assay for α-amylase inhibition

The α-amylase enzyme inhibitory activity was performed using the modification (Luyen et al. 2019) ([Supplementary data](#)).

3.5. Extraction and isolation

Air-dried leaves of *V. amygdalina* (1.2 kg) were extracted with 100% methanol (5 L × 3 times) under sonication at 50 °C for 4 h to yield a dark solid extract (200 g). This extract was suspended in water and successively partitioned with *n*-hexane, dichloromethane and ethyl acetate to give corresponding *n*-hexane (VAH, 52 g), dichloromethane (VAD, 42 g), ethyl acetate (VAE, 31 g) and water layer (VAW, 75 g). The VAE fraction (31 g) was subsequently chromatographed on a silica gel column eluting with dichloromethane/methanol (gradient from 100/1 – 0/1, v/v) to give five fractions (VAE1–VAE5). The VAE1 (1.2 g) fraction was further separated on a silica gel column eluting with dichloromethane/methanol/water (25/1/0.05, v/v/v) to give two smaller fractions (VAE1.1 and VAE1.2). Compound **1** (5 mg) was yielded from VAE1.1 (0.3 g) fraction by purify on a RP-18 column eluting with methanol/water (4/1, v/v). The VAE1.2 (0.2 g) fraction was further separated on a Sephadex LH-20 column eluting with methanol/water (1/1, v/v) to afford compound **3** (15 mg). The VAE2 (0.9 g) fraction was continuously chromatographed on a RP-18 column eluting with methanol/water (3/1, v/v) to yield compounds **2** (7 mg) and **4** (6 mg).




Figure 1. The structures of compounds 1–4.

3.5.1. Vernoamyside E (1)

White amorphous powder, $[\alpha]_D^{20}$ +24.7 (c 0.15, MeOH); IR (KBr) ν_{\max} 3424, 2940, 1598, 1448, 1380; 1H -NMR (MeOD- d_4 , 500 MHz): δ_H 1.34 (1H, m, H_a -1), 1.99 (1H, m, H_b -1), 1.93 (1H, m, H_a -2), 3.71 (1H, m, H_b -2), 3.71 (1H, m, H-3), 1.32 (1H, m, H_a -4), 1.88 (1H, m, H_b -4), 1.41 (1H, m, H-5), 1.61 (1H, m, H_a -6), 1.97 (1H, m, H_b -6), 5.43 (1H, d, $J = 5.0$ Hz, H-7), 5.53 (1H, d, $J = 5.5$ Hz, H-11), 2.04 (1H, m, H_a -12), 2.22 (1H, m, H_b -12), 2.26 (1H, m, H-14), 1.49 (1H, m, H_a -15), 1.86 (1H, m, H_b -15), 1.53 (1H, m, H_a -16), 2.18 (1H, m, H_b -16), 2.08 (1H, m, H-17), 0.57 (3H, s, H-18), 0.93 (3H, s, H-19), 1.89 (1H, m, H-20), 5.43 (1H, d, $J = 5.0$ Hz, H-21), 4.26 (1H, t, $J = 5.5$ Hz, H-22), 4.45 (1H, d, $J = 5.5$ Hz, H-23), 2.20 (1H, m, H-25), 0.94 (3H, d, $J = 7.0$ Hz, H-26), 0.95 (3H, d, $J = 7.0$ Hz, H-27), 1.42 (3H, s, H-29), 4.42 (1H, d, $J = 8.0$, H-1'), 3.18 (1H, m, H-2'), 3.29 (1H, ddd, $J = 2.5, 5.0, 9.5$ Hz, H-3'), 3.32 (1H, m, H-4'), 3.39 (1H, t, $J = 9.0$ Hz, H-5'), 3.70 (1H, dd, $J = 5.5, 12.0$ Hz, H_a -6'), 3.87 (1H, $J = 2.5, 12.0$ Hz, H_b -6') 3.21 (3H, s, OCH₃-28); ^{13}C -NMR (MeOD- d_4 , 125 MHz): δ_C 35.8 (C-1), 30.8 (C-2), 78.9 (C-3), 34.8 (C-4), 40.1 (C-5), 30.3 (C-6), 121.4 (C-7), 137.2 (C-8), 144.8

(C-9), 36.8 (C-10), 119.5 (C-11), 41.9 (C-12), 42.7 (C-13), 51.9 (C-14), 24.2 (C-15), 28.0 (C-16), 45.4 (C-17), 12.9 (C-18), 19.8 (C-19), 50.2 (C-20), 100.0 (C-21), 81.0 (C-22), 91.3 (C-23), 83.2 (C-24), 32.7 (C-25), 17.4 (C-26), 18.1 (C-27), 112.9 (C-28), 17.4 (C-29), 102.6 (C-1'), 74.8 (C-2'), 77.4 (C-3'), 71.4 (C-4'), 77.7 (C-5'), 62.6 (C-6'), 48.3 (OCH₃-28); HR-ESI-MS m/z 687.3708 [M + Na]⁺ (calcd for C₃₆H₅₆NaO₁₁⁺, 687.3720).

Conflict of interest

The authors have declared that there is no conflict of interest.

Funding

This work was supported by Vietnam Academy of Science and Technology under grant number: VAST.NDP.03/17-18).

References

- Atangwho IJ, Ebong PE, Eyong EU, Asmawi MZ, Ahmad M. 2012. Synergistic antidiabetic activity of *Vernonia amygdalina* and *Azadirachta indica*: biochemical effects and possible mechanism. *J Ethnopharmacol.* 141(3):878–887.
- Atangwho IJ, Egbung GE, Ahmad M, Yam MF, Asmawi MZ. 2013. Antioxidant versus anti-diabetic properties of leaves from *Vernonia amygdalina* Del. growing in Malaysia. *Food Chem.* 141(4): 3428–3434.
- Farombi EO, Owoeye O. 2011. Antioxidative and chemopreventive properties of *Vernonia amygdalina* and *Garcinia biflavonoid*. *Int J Environ Res Public Health.* 8(6):2533–2555.
- Fatmawati S, Shimizu K, Kondo R. 2011. Ganoderol B: a potent α -glucosidase inhibitor isolated from the fruiting body of *Ganoderma lucidum*. *Phytomedicine.* 18(12):1053–1055.
- Igile GO, Oleszek W, Jurzysta M, Burda S, Fafunso M, Fasanmade AA. 1994. Flavonoids from *Vernonia amygdalina* and their antioxidant activities. *J Agric Food Chem.* 42(11):2445–2448.
- Jisaka M, Ohigashi H, Takagaki T, Nozaki H, Tada T, Hirota M, Irie R, Huffman MA, Nishida T, Kaji M, Koshimizu K. 1992. Bitter steroid glucosides, vernoniosides A₁, A₂, and A₃, and related B₁ from a possible medicinal plant, *Vernonia amygdalina*, used by wild chimpanzees. *Tetrahedron.* 48(4):625–632.
- Jisaka M, Ohigashi H, Takegawa K, Hirota M, Irie R, Huffman MA, Koshimizu K. 1993. Steroid glucosides from *Vernonia amygdalina*, a possible chimpanzee medicinal plant. *Phytochemistry.* 34(2):409–413.
- Kupchan SM, Hemingway RJ, Karim A, Werner D. 1969. Tumor inhibitors. XLVII. Vernodalin and vernomygdin, two new cytotoxic sesquiterpene lactones from *Vernonia amygdalina* Del. *J Org Chem.* 34(12):3908–3911.
- Liu X, Tian W, Wang G, Xu Q, Zhou M, Gao S, Qiu D, Jiang X, Sun C, Ding R, et al. 2019. Stigmastane-type steroids with unique conjugated $\Delta^{7,9(11)}$ diene and highly oxygenated side chains from the twigs of *Vernonia amygdalina*. *Phytochemistry.* 158:67–76.
- Luyen NT, Binh PT, Tham PT, Hung TM, Dang NH, Dat NT, Thao NP. 2019. Wedtrilosides A and B, two new diterpenoid glycosides from the leaves of *Wedelia trilobata* (L.) Hitchc. with α -amylase and α -glucosidase inhibitory activities. *Bioorg Chem.* 85:319–324.
- Ma GX, Feng W, Sun ZH, Li PF, Zhu NL, Yang JS, Xu XD, Wu HF. 2016. New stigmastane type of steroidal glycosides from the roots of *Vernonia cumingiana*. *J Carbohydr Chem.* 35(3):172–179.
- Park SR, Kim JH, Jang HD, Yang SY, Kim YH. 2018. Inhibitory activity of minor phlorotannins from *Ecklonia cava* on α -glucosidase. *Food Chem.* 257:128–134.
- Quasie O, Zhang Y-M, Zhang HJ, Luo J, Kong LY. 2016. Four new steroid saponins with highly oxidized side chains from the leaves of *Vernonia amygdalina*. *Phytochem Lett.* 15:16–20.

- Saliu J, Ademiluyi A, Akinyemi A, Oboh G. 2012. In vitro antidiabetes and antihypertension properties of phenolic extracts from bitter leaf (*Vernonia amygdalina* Del.). J Food Biochem. 36(5): 569–576.
- Taiwo IA, Godwin P, Odeigah C, Jaja SI, Mojiminiyi FB. 2009. Cardiovascular effects of *Vernonia amygdalina* in rats and the implications for treatment of hypertension in diabetes. Researcher. 2:76–79.
- Thao NP, Luyen BTT, Jo SH, Hung TM, Cuong NX, Nam NH, Kwon YI, Van Minh C, Kim YH. 2014. Triterpenoid saponins from the roots of *Rosa rugosa* Thunb. as rat intestinal sucrase inhibitors. Arch Pharm Res. 37(10):1280–1285.
- Yeap SK, Ho WY, Beh BK, Liang WS, Ky H, Yousr AHN, Alitheen NB. 2010. *Vernonia amygdalina*, an ethnoveterinary and ethnomedical used green vegetable with multiple bio-activities. J Med Plants Res. 4:2787–2812.